Dr.ย Tamarย Peretz
MD (Doctor of Medicine)
Professor of Oncology & Senior Breast Cancer Specialist
corporate_fareHadassah Medical Center, Jerusalem
Tamar Peretz
MD (Doctor of Medicine)
Prof. Tamar Peretz is one of Israel's most respected breast cancer oncologists, known for her decades of clinical and research work in breast cancer, hereditary cancer genetics, and BRCA1/BRCA2 mutation-associated disease. She is a senior specialist at the Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, and Professor of Oncology at the Hebrew University of Jerusalem.
With over 30 years of experience in medical and radiation oncology, Prof. Peretz has contributed substantially to advancing breast cancer care in Israel and internationally. She previously served as Director of the Sharett Institute of Oncology at Hadassah Medical Center, overseeing one of Israel's foremost cancer treatment and research programmes. Her clinical and scientific work has been especially important in understanding hereditary breast and ovarian cancer risk, BRCA founder mutations among Ashkenazi Jewish women, and personalised treatment planning based on tumour biology and inherited cancer susceptibility. She brings a multidisciplinary perspective, combining training in both medical oncology and radiation oncology, and has been a central figure in integrating genomic and genetic evaluation into breast cancer care at Hadassah.
Why Consider Prof. Tamar Peretz?
Prof. Peretz combines rare depth in both clinical breast oncology and hereditary cancer genetics, making her one of the most relevant specialists for patients with complex breast cancer, BRCA-positive disease, or a strong family history of breast and ovarian cancer.
Areas of Specialisation
Breast cancer, hereditary cancer genetics, and personalised oncology at Hadassah Medical Center
Prof. Peretz's clinical expertise spans the full spectrum of breast cancer management and hereditary cancer risk assessment, with particular depth in BRCA-related disease and Ashkenazi Jewish cancer genetics.
Breast Cancer โ All Subtypes
Comprehensive medical oncology and radiation oncology-informed management of breast cancer across stages and molecular subtypes.
- arrow_rightNeoadjuvant and adjuvant chemotherapy planning
- arrow_rightHormonal therapy for oestrogen and progesterone receptor-positive disease
- arrow_rightHER2-targeted therapy for HER2-positive tumours
- arrow_rightRadiation oncology integration and post-surgical planning
- arrow_rightSystemic therapy sequencing for advanced disease
- arrow_rightPARP inhibitor therapy for BRCA-mutated metastatic breast cancer
- arrow_rightImmunotherapy discussion where clinically indicated
- arrow_rightRecurrence-risk evaluation and long-term management planning
BRCA Mutations & Hereditary Cancer Genetics
Expert evaluation and clinical management for patients with BRCA1 or BRCA2 mutations or a strong hereditary breast and ovarian cancer history.
- arrow_rightIdentifying patients suitable for BRCA1/BRCA2 genetic testing
- arrow_rightInterpreting hereditary cancer risk in clinical context
- arrow_rightPreventive strategies for high-risk women and carriers
- arrow_rightRisk-adapted surveillance and early detection planning
- arrow_rightSpecialist knowledge of BRCA founder mutations prevalent in Ashkenazi Jewish ancestry
- arrow_rightPopulation-informed risk counselling and clinical decision-making
- arrow_rightHereditary breast and ovarian cancer syndrome evaluation
Personalised & Radiation-Informed Oncology
Treatment planning guided by tumour biology, molecular markers, genetic background, and integrated medical and radiation oncology knowledge.
- arrow_rightBiomarker and receptor status-guided systemic therapy selection
- arrow_rightGenomic risk assessment tools for chemotherapy decision-making
- arrow_rightIndividualised treatment planning across early and advanced stages
- arrow_rightIntegration of medical oncology, radiation oncology, surgery, genetics, and pathology
- arrow_rightTumour board participation and multidisciplinary case review
- arrow_rightSurvivorship care planning and long-term follow-up
Procedures & Clinical Services
Medical oncology, genetic evaluation, and multidisciplinary breast cancer care
Prof. Peretz's clinical services span systemic therapy planning, genetic risk consultation, radiation oncology collaboration, and expert second opinion for complex breast cancer cases.
Breast Cancer Systemic Therapy
Medical OncologyComprehensive planning and administration of systemic cancer treatment tailored to breast cancer subtype, stage, and patient profile.
Targeted Therapy & PARP Inhibition
Targeted TherapyMolecularly guided systemic therapy for patients with specific genetic mutations or tumour biomarkers.
Hereditary Cancer Risk Evaluation
DiagnosisStructured evaluation of hereditary cancer risk, genetic testing guidance, and preventive planning for high-risk patients and families.
Second Opinion โ Breast Cancer
Second OpinionExpert independent review of breast cancer diagnosis, pathology, staging, and treatment planning.
Research & Publications
Hereditary breast cancer genetics, BRCA research, and clinical oncology contributions
Prof. Peretz has been a leading contributor to breast cancer research in Israel, with a particular focus on hereditary cancer genetics, BRCA1/BRCA2 mutations, and cancer risk among Ashkenazi Jewish women. As Professor of Oncology at the Hebrew University of Jerusalem, she has also contributed to medical education and the training of oncology specialists.
A detailed publication list for Prof. Peretz may be available through PubMed or the Hebrew University of Jerusalem. CancerFax can assist in preparing your case for submission to the Hadassah breast oncology team.
Education & Training
Prof. Peretz trained in medicine and oncology at the Hebrew University Hadassah Medical School in Jerusalem, subsequently undertaking international training to build her expertise in medical oncology, radiation oncology, and hereditary cancer genetics.
Clinical Experience
Prof. Peretz has spent her entire clinical career at Hadassah Medical Center in Jerusalem, building one of Israel's most respected breast oncology and hereditary cancer programmes over more than 30 years.
Languages & International
Prof. Peretz conducts consultations in the following languages.
CancerFax coordinates professional medical interpreter support for international patients who require assistance in languages beyond English and Hebrew.
CancerFax can coordinate professional medical interpreter support for patients consulting in Arabic, Russian, French, and other languages.
How CancerFax Helps You Access Dr. Tamar Peretz
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Tamar Peretz's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Tamar Peretz's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Tamar Peretz before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Tamar Peretz's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Tamar Peretz's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Tamar Peretz's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Tamar Peretz
CancerFax can coordinate medical record review and consultation support for international patients seeking an expert breast cancer opinion from Prof. Peretz at Hadassah Medical Center in Jerusalem. Consultation is subject to hospital availability and case acceptance. CancerFax assists with case preparation, document translation, and logistics coordination.
Prof. Peretz specialises in breast cancer across all stages and subtypes, including early-stage, locally advanced, metastatic, triple-negative, hormone receptor-positive, and HER2-positive breast cancer. She has particular expertise in BRCA1 and BRCA2 mutation-associated hereditary breast and ovarian cancer, and is internationally recognised for her work in Ashkenazi Jewish cancer genetics.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured medical summary, and coordinate the consultation process with the Hadassah breast oncology team. Typical documents required include pathology reports, receptor status (ER, PR, HER2, Ki-67), imaging, BRCA test results if available, and treatment history.
A second-opinion request can be submitted through CancerFax with your complete pathology reports, histopathology and immunohistochemistry results, imaging (mammogram, MRI, PET-CT, CT), treatment history, and any genetic test results. Prof. Peretz and the Hadassah team can review the case and provide an independent expert opinion. Final consultation format and availability depend on the hospital's scheduling.
Prof. Peretz is one of Israel's leading specialists in BRCA1 and BRCA2 mutation-associated cancer. She has dedicated a significant part of her research career to understanding hereditary breast and ovarian cancer risk, particularly among Ashkenazi Jewish women who carry higher rates of specific BRCA founder mutations. Clinically, she helps patients understand genetic test results, navigate preventive options, and receive personalised treatment planning that accounts for their inherited cancer risk.
Prof. Peretz plans and oversees a full range of medical oncology treatments for breast cancer, including chemotherapy, hormonal therapy, HER2-targeted agents (trastuzumab, pertuzumab, T-DM1), PARP inhibitors for BRCA-mutated disease (olaparib, talazoparib), and CDK4/6 inhibitors for hormone receptor-positive advanced disease. Treatment decisions are guided by receptor status, molecular profiling, genetic background, disease stage, and patient preferences, within a multidisciplinary care framework.
Connect with Tamar Peretz Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.